Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 2c, Revenues Miss; Offers FY20 Revenue Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 2c, Revenues Miss; Offers FY20 Revenue Outlook

Vanda Pharmaceuticals Reports Third Quarter 2020 Financial Results

October 28, 2020 4:01 PM EDT

WASHINGTON, Oct. 28, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2020.

"Vanda continued to deliver strong commercial performance in the third quarter, despite the ongoing COVID-19 pandemic, while at the same time we advanced our robust clinical development pipeline," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO.

Key Financial and Corporate Highlights 

Third Quarter of 2020

Total net product sales from HETLIOZ® and Fanapt® were $60.3 million in the third quarter of... More